Prescient Therapuetics Investor Briefing – 16 February

February 16, 2022

Prescient Therapuetics Investor Briefing – 16 February

Prescient Therapuetics Limited (ASX: PTX) Webcast Replay

16th February, 2022

Prescient Therapeutics Limited (ASX: PTX) is a company taking the cancer conversation from ‘fight’ to ‘cure’ with its next-generation cancer therapy and treatments.

As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Steven Yatomi-Clarke provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 16th February 2022 at 12pm (AEDT).

Join the next The Insider: Meet the CEOs webcast

Speak to the Reach Markets team


Steven Yatomi-Clarke

CEO - Prescient Therapuetics Limited (ASX: PTX)

Prescient Therapeutics is a clinical-stage oncology company focused on developing novel, personalised therapies for a range of cancers. The company is conducting ongoing clinical trials and manufacturing for its PTX-100 and PTX-200 targeted cancer therapies. Prescient has collaborated with the world-leading Peter Mac cancer centre to develop a next-generation OmniCAR cell therapy that is capable of reshaping cancer treatment. In December 2021, the company announced a strong cash position of $14.77 million and newly gained accreditation that enables clinical studies for OmniCAR.

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.